

CpG 7909 Adjuvant

Catalog No. NR-52393

This reagent is the property of the U.S. Government.

For research use only. Not for use in humans.

Contributor:

Josh Reece, Ph.D., Senior Director, Vaccine Research & Development, Emergent BioSolutions, Gaithersburg, Maryland, USA

Manufacturer:

Nitto Denko AVECIA, Inc., Milford, Massachusetts, USA

Product Description:

CpG 7909 oligodeoxynucleotide is an immunostimulatory, toll-like receptor 9 (TLR9) agonist used as an adjuvant for screening with different vaccine antigens.^{1,2,3,4} This 24-mer B-Class CpG oligodeoxynucleotide has been used to augment the immunogenicity in vaccines developed to treat anthrax, cancer, hepatitis B, influenza and malaria.^{1,4} CpG 7909 was manufactured at AVECIA through a contract with Emergent BioSolutions.¹

Material Provided:

Each vial contains approximately 0.5 mL of CpG 7909 adjuvant in nuclease-free water. **Note:** NR-52393 should be used as soon as possible, as the long-term stability of reconstituted CpG 7909 adjuvant without a cryoprotectant is not known.¹

Packaging/Storage:

NR-52393 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: CpG 7909 Adjuvant, NR-52393."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Reece, J. and V. Rao, Personal Communication.
2. Shirota, H. and D. M. Klinman. "Recent Progress Concerning CpG DNA and Its Use as a Vaccine Adjuvant." Expert Rev. Vaccines 13 (2014): 299-312. PubMed: 24308579.
3. Bode, C., et al. "CpG DNA as a Vaccine Adjuvant." Expert Rev. Vaccines 10 (2011): 499-511. PubMed: 21506647.
4. Scheiermann, J. and D. M. Klinman. "Clinical Evaluation of CpG Oligonucleotides as Adjuvants for Vaccines Targeting Infectious Diseases and Cancer." Vaccine 32 (2014): 6377-6389. PubMed: 24975812.

ATCC® is a trademark of the American Type Culture Collection.

